Alnylam Pharmaceuticals Stock Today

ALNY Stock  USD 154.39  2.42  1.59%   

Performance

0 of 100

 
Low
 
High
Very Weak

Odds Of Distress

Less than 27

 
100  
 
Zero
Below Average
Alnylam Pharmaceuticals is trading at 154.39 as of the 28th of March 2024; that is 1.59 percent increase since the beginning of the trading day. The stock's open price was 151.97. Alnylam Pharmaceuticals has about a 27 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Alnylam Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 8th of April 2022 and ending today, the 28th of March 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
28th of May 2004
Category
Healthcare
Classification
Health Care
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. The company has 125.95 M outstanding shares of which 2.69 M shares are presently shorted by private and institutional investors with about 2.3 trading days to cover. More on Alnylam Pharmaceuticals

Moving together with Alnylam Stock

  0.83MCRB Seres Therapeutics Financial Report 14th of May 2024 PairCorr
  0.82KA Kineta Inc Report 29th of March 2024 PairCorr

Moving against Alnylam Stock

  0.93EQ Equillium Financial Report 9th of May 2024 PairCorr
  0.92DNTH Dianthus Therapeutics Symbol ChangePairCorr
  0.86MGNX MacroGenics Financial Report 14th of May 2024 PairCorr
  0.79MDWD Mediwound Financial Report 4th of June 2024 PairCorr
  0.72TCRX Tscan Therapeutics Financial Report 8th of May 2024 PairCorr
  0.71MRK Merck Company Fiscal Quarter End 31st of March 2024 PairCorr
  0.61VANI Vivani Medical Report 29th of March 2024 PairCorr

Alnylam Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Alnylam Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Alnylam Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CEO, DirectorJohn Maraganore
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, ARCA Biotechnology, Dow Jones Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Analysts covering Alnylam Pharmaceuticals report their recommendations after researching Alnylam Pharmaceuticals' financial statements, talking to executives and customers, or listening in on Alnylam Pharmaceuticals' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Alnylam Pharmaceuticals. The Alnylam consensus assessment is calculated by taking the average forecast from all of the analysts covering Alnylam Pharmaceuticals.
Financial Strength
Based on the key indicators related to Alnylam Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Alnylam Pharmaceuticals may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. Financial strength of Alnylam Pharmaceuticals is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.50.4774
Sufficiently Up
Slightly volatile
Gross Profit Margin0.960.8302
Fairly Up
Slightly volatile
Total Current LiabilitiesB967.8 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total3.2 B3.1 B
Sufficiently Up
Slightly volatile
Total AssetsB3.8 B
Sufficiently Up
Slightly volatile
Total Current Assets3.1 BB
Sufficiently Up
Slightly volatile
Alnylam Pharmaceuticals' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Alnylam Pharmaceuticals' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Alnylam Pharmaceuticals' financial leverage. It provides some insight into what part of Alnylam Pharmaceuticals' total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on Alnylam Pharmaceuticals' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Alnylam Pharmaceuticals deploys its capital and how much of that capital is borrowed.
Liquidity
Alnylam Pharmaceuticals cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 2.68 B in liabilities with Debt to Equity (D/E) ratio of 5.63, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Alnylam Pharmaceuticals has a current ratio of 3.41, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Alnylam Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Alnylam Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Alnylam Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Alnylam to invest in growth at high rates of return. When we think about Alnylam Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Total Cash From Financing Activities

163.52 Million
Alnylam Pharmaceuticals (ALNY) is traded on NASDAQ Exchange in USA. It is located in 675 West Kendall Street, Cambridge, MA, United States, 02142 and employs 2,100 people. Alnylam Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 19.08 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Alnylam Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Alnylam Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Alnylam Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 125.95 M outstanding shares of which 2.69 M shares are presently shorted by private and institutional investors with about 2.3 trading days to cover. Alnylam Pharmaceuticals currently holds about 2.27 B in cash with 104.16 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 18.41.
Check Alnylam Pharmaceuticals Probability Of Bankruptcy
Ownership Allocation
Alnylam Pharmaceuticals holds a total of 125.95 Million outstanding shares. The majority of Alnylam Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Alnylam Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Alnylam Pharmaceuticals. Please pay attention to any change in the institutional holdings of Alnylam Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Alnylam Ownership Details

Alnylam Stock Price Odds Analysis

Based on a normal probability distribution, the odds of Alnylam Pharmaceuticals jumping above the current price in 90 days from now is about 79.34%. The Alnylam Pharmaceuticals probability density function shows the probability of Alnylam Pharmaceuticals stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Alnylam Pharmaceuticals has a beta of 0.8131. This suggests as returns on the market go up, Alnylam Pharmaceuticals average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Alnylam Pharmaceuticals will be expected to be much smaller as well. Additionally, alnylam Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming NYSE Composite.
  Odds Below 154.39HorizonTargetOdds Above 154.39
20.56%90 days
 154.39 
79.34%
Based on a normal probability distribution, the odds of Alnylam Pharmaceuticals to move above the current price in 90 days from now is about 79.34 (This Alnylam Pharmaceuticals probability density function shows the probability of Alnylam Stock to fall within a particular range of prices over 90 days) .

Alnylam Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Alnylam Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Alnylam Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Alnylam Pharmaceuticals' value.
InstituionRecorded OnShares
Jpmorgan Chase & Co2023-12-31
M
Capital Research Global Investors2023-12-31
2.9 M
Norges Bank2023-12-31
M
Geode Capital Management, Llc2023-12-31
1.9 M
Rtw Investments, Llc2023-12-31
1.6 M
Venbio Select Advisor Llc2023-12-31
1.1 M
Legal & General Group Plc2023-12-31
930.9 K
Pictet Asset Manangement Sa2023-12-31
885.6 K
Bellevue Group Ag2023-12-31
885.3 K
Capital World Investors2023-12-31
16.2 M
Vanguard Group Inc2023-12-31
11.9 M
View Alnylam Pharmaceuticals Diagnostics

Alnylam Pharmaceuticals Historical Income Statement

Alnylam Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Alnylam's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Alnylam Pharmaceuticals revenue and expense. Alnylam Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Alnylam Pharmaceuticals' Tax Provision is fairly stable compared to the past year. View More Fundamentals

Alnylam Stock Against Markets

Picking the right benchmark for Alnylam Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Alnylam Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Alnylam Pharmaceuticals is critical whether you are bullish or bearish towards Alnylam Pharmaceuticals at a given time. Please also check how Alnylam Pharmaceuticals' historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Alnylam Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Stocks Directory Now

   

Stocks Directory

Find actively traded stocks across global markets
All  Next Launch Module

Alnylam Pharmaceuticals Corporate Directors

Alnylam Pharmaceuticals corporate directors refer to members of an Alnylam Pharmaceuticals board of directors. The board of directors generally takes responsibility for the Alnylam Pharmaceuticals' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Alnylam Pharmaceuticals' board members must vote for the resolution. The Alnylam Pharmaceuticals board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.

How to buy Alnylam Stock?

Before investing in Alnylam Pharmaceuticals, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Alnylam Pharmaceuticals. To buy Alnylam Pharmaceuticals stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Alnylam Pharmaceuticals. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Alnylam Pharmaceuticals stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Alnylam Pharmaceuticals stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Alnylam Pharmaceuticals stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Alnylam Pharmaceuticals, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.

Already Invested in Alnylam Pharmaceuticals?

The danger of trading Alnylam Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Alnylam Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Alnylam Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Alnylam Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Alnylam Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alnylam Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alnylam Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alnylam Pharmaceuticals Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alnylam Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Complementary Tools for Alnylam Stock analysis

When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Is Alnylam Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alnylam Pharmaceuticals. If investors know Alnylam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alnylam Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.53)
Revenue Per Share
14.637
Quarterly Revenue Growth
0.312
Return On Assets
(0.05)
Return On Equity
(15.01)
The market value of Alnylam Pharmaceuticals is measured differently than its book value, which is the value of Alnylam that is recorded on the company's balance sheet. Investors also form their own opinion of Alnylam Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Alnylam Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alnylam Pharmaceuticals' market value can be influenced by many factors that don't directly affect Alnylam Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alnylam Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alnylam Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alnylam Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.